Ocugen, Phase 1
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME).
Shares of Ocugen Inc. OCGN slid 1.91% to $0.72 Thursday, on what proved to be an all-around rough trading session for the ...
On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...
Ocugen (OCGN) announced a positive 2-year safety and efficacy update for the Phase 1/2 OCU400 clinical trial. OCU400 is intended for the ...
Ocugen Inc. closed $1.21 below its 52-week high ($2.11), which the company achieved on March 25th.
Maxim Group has recently initiated Ocugen Inc (OCGN) stock to Buy rating, as announced on October 15, 2024, according to Finviz. Earlier, on March 1, 2023, Chardan Capital Markets had raised the stock ...
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...
Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...
Hosted on MSN3d
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaMALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback